Shionogi & Co., Ltd.
FY2025 Financial Results Explanation Materials
In FY2025, revenue reached 499.7 billion yen (up 14.0% YoY), operating income was 166.7 billion yen (up 6.5% YoY), and net income attributable to owners of the parent was 205.2 billion yen (up 20.4% YoY), marking record highs.
Key Figures
- Revenue: 499.7 billion yen (up 14.0% YoY)
- Operating Income: 166.7 billion yen (up 6.5% YoY)
- Net Income Attributable to Owners of the Parent: 205.2 billion yen (up 20.4% YoY)
AI要約
FY2025 Financial Highlights
In FY2025, revenue was 499.7 billion yen (up 14.0% YoY), operating income was 166.7 billion yen (up 6.5% YoY), pre-tax profit was 238.9 billion yen (up 19.0% YoY), and net income attributable to owners of the parent was 205.2 billion yen (up 20.4% YoY), all reaching record highs. EBITDA was 187.7 billion yen (up 4.7% YoY). The main factors contributing to the increase in revenue include higher royalty income, increased exports and overseas subsidiaries of domestic pharmaceuticals, and sales expansion of Torii Pharmaceuticals.
FY2026 Earnings Forecast
In FY2026, revenue is projected to be 700.0 billion yen (up 40.1% YoY), operating income 220.0 billion yen (up 32.0% YoY), pre-tax profit 220.0 billion yen (down 7.9% YoY), and net income attributable to owners of the parent 210.0 billion yen (up 2.4% YoY). Revenue and operating income are expected to reach record highs for five consecutive years. The exchange rates are based on USD 1 = 153.0 yen, GBP 1 = 205.0 yen, and EUR 1 = 184.0 yen.
Revenue Trend (Billion Yen)
Operating Income Trend (Billion Yen)
Net Income Attributable to Owners of the Parent Trend (Billion Yen)
FY2025 Segment Revenue Breakdown (Billion Yen)
FY2026 Earnings Forecast vs. FY2025 Actuals (Billion Yen)
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
